FASN and neoplasm: The results confirm that antagomir‐EBV‐miR‐BART18‐3p decreased EBV‐miR‐BART18‐3p expression and also demonstrate that antagomir‐EBV‐miR‐BART18‐3p decreased the levels of LDHA and FASN, as well as Ki67 (a recognized tumor malignant phenotype marker[49]) in tumor tissues (Figure 6E,F).